Autoimmune pulmonary pleurisy is an inflammatory condition where the body’s defensive system attacks the membrane that covers and protects the lungs. In an optimal health condition, the two layers of the pleura slide without friction thanks to a minimal amount of lubricating fluid. However, this biological mechanism is altered when the immune system generates a disproportionate inflammatory response against the pleural tissue. This pathology is usually linked to systemic diseases, with systemic lupus erythematosus (SLE) being the most common cause identified in clinical practice. Therefore, the pleura thickens and becomes rough, losing its ability for smooth movement during respiration. Consequently, the result is a sharp, localized pain that limits the lung capacity of the affected patient.
Moreover, the most characteristic symptom of this condition is pleuritic pain, which intensifies drastically when taking deep breaths. It is important to highlight that any movement of the torso, such as coughing or sneezing, can exacerbate the sensation of pressure in the chest cavity. Nevertheless, the inflammation not only causes pain but can also alter the balance of internal fluids. As a result, it is common for a pleural effusion to occur, where excess fluid accumulates in the space between the membrane layers. This resulting shortness of breath is due to the lung’s inability to fully expand because of the external pressure from the fluid.
For this reason, autoimmune pleurisy usually presents alongside a persistent dry cough that is not related to common respiratory infections. In view of this, differential diagnosis is key to distinguishing this inflammation from pneumonia or physical trauma. Due to this autoimmune disease, treatment is not limited to soothing the pain but requires the regulation of the overall immune system. On the other hand, the use of corticosteroids and immunosuppressants is usually very effective in reducing pleural inflammation and stopping the effusion. Accordingly, detecting specific antibodies in the blood helps confirm if lupus is the main trigger of the clinical picture.
Finally, the comprehensive management of autoimmune pulmonary pleurisy seeks to restore respiratory function and prevent chronic damage to the lung tissue. Although the inflammation can be recurrent in patients with lupus, an adequate preventive treatment minimizes the frequency of the crises. In summary, understanding how autoimmune processes affect serous membranes is fundamental for the patient’s well-being. Ultimately, the main goal is to reduce pleural irritation so that the act of breathing becomes a natural and painless process once again. Lastly, constant follow-up by specialists in rheumatology and pulmonology ensures optimal control of the disease.